MedTrace Logo

Current Pharmacological Practices in Severe COVID-19

NCT04691921 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1055

Last updated 2021-02-16

No results posted yet for this study

Summary

The investigators aim to understand the variation in pharmacological therapies for the management of severe coronavirus disease 2019 (COVID-19) in India and compare it to the recent available evidence.

The ongoing pandemic of COVID-19 has proven to be the greatest medical emergency of recent times. The evidence on the therapeutics has evolved significantly in last few months after initial use of re-purposed drugs.

The objective of this study is to understand the current practices in the management of adults severe COVID-19 in India.

Conditions

Interventions

BEHAVIORAL

Current clinical practices of participating physicians

Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19

Sponsors & Collaborators

  • NMC Specialty Hospital

    lead OTHER

Principal Investigators

  • Prashant Nasa, MD EDICM · NMC Specialty Hospital

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2021-01-18
Completion
2021-01-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04691921 on ClinicalTrials.gov